• Boston Scientific’s Watchman heart device is increasingly being implanted during combined cardiac procedures instead of as a standalone treatment.
• This shift in medical practice has reduced standalone Watchman procedure volumes and is expected to keep revenue for the product line roughly flat through Q3 2026.
• The change reflects how doctors are rethinking procedure planning, with implications for Boston Scientific’s growth mix and product planning.

For investors watching Boston Scientific (NYSE:BSX), the Watchman update comes at a time when the stock has been under pressure. The share price is around $45.6, with the stock down 21.1% over the past month and down 51.9% year to date. Over a 1-year period, the stock is down 56.2%, while the 5-year return is up 5.5%.

The new pattern of combining Watchman with other heart procedures could reshape how this product contributes to Boston Scientific’s results beyond routine quarterly noise. Flat revenue expectations for Watchman through Q3 2026 put more focus on how the company balances this shift with other product lines and capital allocation choices. Investors may want to track whether this combined procedure approach becomes a lasting standard of care and how Boston Scientific responds.

Stay updated on the most important news stories for Boston Scientific by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Boston Scientific.

The Watchman shift is important for Boston Scientific because it affects both near term revenue expectations and how investors think about the company’s growth mix. With management guiding to roughly flat Watchman revenue through Q3 2026 and several brokers cutting price targets, the stock’s recent share price decline reflects more than just short term sentiment. Investors are reassessing how much of the previous growth story was tied to procedure volume in left atrial appendage closure versus other parts of the portfolio, particularly as peers like Abbott and Medtronic also face pressure in medical devices.

How This Fits Into The Boston Scientific Narrative

• The Watchman update ties directly into the narrative’s focus on advanced therapies like FARAPULSE and Watchman, showing how real world clinical practice patterns can influence the contribution from these high value products.
• Flat Watchman expectations and softer utilization challenge the idea that advanced cardiac procedures will steadily support above market procedure growth without interruption.
• The narrative pays more attention to broader portfolio expansion and acquisitions such as Axonics and Silk Road, while this shift in combined procedure planning may not be fully reflected in how left atrial appendage closure volumes are modeled.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Boston Scientific to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ A key risk is that a prolonged slowdown in Watchman procedures, coupled with softer electrophysiology trends, could keep Boston Scientific’s overall growth below what some investors previously expected.
• ⚠️ Analysts have highlighted concerns that repeated estimate cuts across Watchman and electrophysiology could weigh on confidence in Boston Scientific’s ability to hit its longer term revenue targets.
• 🎁 A potential reward is that Boston Scientific still has a diversified cardiovascular and MedSurg portfolio, which some analysts continue to view as supportive even as Watchman expectations are reset.
• 🎁 Another reward is that with the stock down sharply over 1 year, investors who agree with the more constructive analyst narratives may see reset expectations as creating scope for sentiment to improve if execution stabilizes.

What To Watch Going Forward

From here, investors in Boston Scientific may want to track a few things closely. First, whether combined Watchman procedures stabilize overall device utilization, even if standalone volumes are lower. Second, how guidance and commentary around electrophysiology evolve, particularly relative to competitors such as Abbott and Medtronic. Third, whether management continues with buybacks and acquisitions on the same scale, or prioritizes balance sheet flexibility while key product lines reset. Together, these signals will help indicate whether the Watchman slowdown is a contained issue or part of a broader reset in Boston Scientific’s growth profile.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Boston Scientific, head to the community page for Boston Scientific to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.